Over 1.8 million nonprofits and charities for donors, volunteers and funders

Claim This Nonprofit

More Info

Add to Favorites

Share this Nonprofit

Donate

Volunteering Oportunities

Nonprofit Overview

Causes: Government & Public Administration, Health, Medical Research, Mental Health, Mental Health Treatment

Mission: Founded in 1986, the Multidisciplinary Association for Psychedelic Studies (MAPS) is a 501(c)(3) non-profit research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana. MAPS furthers its mission by: -Developing psychedelics and marijuana into prescription medicines -Training therapists and working to establish a network of treatment centers -Supporting scientific research into spirituality, creativity, and neuroscience -Educating the public honestly about the risks and benefits of psychedelics and marijuana MAPS envisions a world where psychedelics and marijuana are safely and legally available for beneficial uses, and where research is governed by rigorous scientific evaluation of their risks and benefits.

Results: MAPS has completed two Phase 2 FDA studies using MDMA-assisted psychotherapy to treat PTSD, and is in the process of four other similar studies. MAPS also has a study looking at LSD-assisted psychotherapy for treating end-of-life anxiety, an outcome study of the benefits of ibogaine for opiate dependence, and a protocol to investigate medical marijuana to relieve symptoms of PTSD.

Target demographics: Any person whose life may be aided by the transformative nature of psychedelic psychotherapy

Geographic areas served: Worldwide

Programs: Maps' primary focus is research into mdma-assisted psychotherapy ($1,094,575), especially phase 2 research into mdma-assisted psychotherapy in subjects with chronic, treatment-resistant ptsd. In this fiscal year, maps treated the 18th subject in our charleston, south carolina mdma/ptsd study in 24 veterans, firefighters and police officers. An 8th subject was treated in our study in boulder, colorado for people suffering from ptsd from any source, a fourth subject was treated in our mdma/ptsd study in beer yaakov, israel, and an irb approved the amendments for our mdma/ptsd study in vancouver, canada. A 7th therapist participated in our mdma-assisted psychotherapy therapist training study. In addition to our core clinical research, this fiscal year we began planning a series of studies in collaboration with researchers who work with the u. S. Department of veterans affairs' national center for ptsd. We'll be exploring the use of mdma along with more traditional psychotherapeutic methods for treating ptsd including cognitive-behavioral conjoint therapy, cognitive processing therapy, and prolonged exposure therapy. We also began our study looking at the safety and efficacy of using mdma-assisted therapy for anxiety in adults on the autism spectrum and began preparations for a study of mdma-assisted psychotherapy for end-of-life anxiety. These studies will grow significantly in the coming year. Mdma-study related program expenses include costs of video data storage and streaming systems development, budgeting, contracting, and meetings; the costs of developing the treatment manual; training therapists; blinded therapist adherence training; and costs of reviewing and documenting all published mdma literature. There are also mdma-study related supervision of therapists, presentation of our data at professional conferences, and costs to manage the mdma purchased early in our work and to secure the drug for phase 3 trials expected to begin in 2016. Clinical research general costs cover the development of the infrastructure needed for our mdma clinical trials, including work with communications and fundraising departments, staff professional development and conferences, and video streaming and statistical software. Most of the clinical research expenses are personnel, including personnel at each study site: principal investigators, co-investigators, independent raters, overnight physicians, attendant, and study coordinators, as well as maps' internal staff: the clinical director, research associates, information specials, data coordinators and statistical consultants. Ibogaine research expenses were dedicated to completing our studies in mexico ($3,816), and new zealand ($6,329). Lsd research expenses ($12,185) were primarily used for the march 2014 publication of our lsd end-of-life anxiety article in the journal of nervous and mental disease. Marijuana research ($14,905) covered the costs of developing the protocol for a pilot study in which marijuana will be tested to manage symptoms in 76 veterans with chronic, treatment-resistant ptsd, and our efforts to end the public health service (phs) review and the national institute of drug abuse (nida) monopoly of the sale of marijuana for clinical research.

education expenses include harm reduction, events, publications and communications programs. Our zendo project provides a supportive space for people undergoing difficult psychedelic experiences in order to help turn those experiences into opportunities for learning and personal growth, and to reduce the number of drug-related psychiatric hospitalizations and arrests. Services were provided at five major events in fiscal year 2014: burning man (black rock city, nv), envision (costa rica), afrikaburn (south africa), bicycle day (san francisco, ca), and lightning in a bottle (bradley, ca). In order to share recent findings and to inspire existing and new support, maps produced events on psychedelic and marijuana research in colorado, vancouver and santa cruz; and attended more than 17 events that others produced, providing speakers, exhibits, sales of books and maps bulletins, and free distribution of clinical protocols and articles from peer-reviewed journals. Communications included publishing three maps bulletins, and 12 email newsletters, maintaining maps. Org, mdmaptsd. Org, mapscanada. Org, psychedelicscience. Org, and launching mdma-autism. Org. Maps produced "manifesting minds," with north atlantic books, reprinted albert hofmann's "lsd: my problem child," and began work with stanislav grof on his new book, "the visionary world of h. R. Giger. " in spring 2014, maps offered its first webinar, "psychedelic science," in collaboration with evolver learning labs. Maps saw significant growth in coverage of its work in social, online, and traditional media. Maps. Org had 511,449 unique visits and 1,809,246 page views. Facebook likes more than doubled to 89,282. Twitter followers increased 140%, to 17,099. Youtube subscriptions increased 256% to 5,313. Maps received 344 unique media mentions from online and print publications with significant reach. Media outlets include the los angeles times, the new york times, the san francisco chronicle, reason, scientific american, cnn, usa today, msnbc, time, associated press, fox news, forbes, nbc news, playboy, santa cruz sentinel, tricycle, business insider, npr, vice, and southern california public radio (kpcc).

this year, maps operationalized its long-running fiscal sponsorship program, clarifying and updating contracts, process, and structure. This program supports projects that are in alignment with maps mission and vision by offering donors a way to give to a 501(c) 3 nonprofit organization. Maps monitors the project budget, takes a small fee, and sends the donor a receipt for their contribution.

Community Stories

13 Stories from Volunteers, Donors & Supporters

1

Client Served

Rating: 5

Like many young researchers working in the field of neuroscience, I believe that there are therapeutic benefits these psychedelic drugs have to offer for mental health issues. However, it is quite clear that the majority of the current field is somewhat close minded to the idea that these illegal 'recreational' substances have potential. But thanks to MAPS, with its reputable members, high profile studies and intelligent marketing, I can certainly see that the tide is changing. This research and support is clearly not only vital for ameliorating mental illness worldwide, but is also important for the universal understanding of human consciousness.

1

Client Served

Rating: 5

Without the scientific research and sensible approach to psychedelics, I would have died from scleroderma instead of finding a cure and I wouldn't have been able to help my friends cure their diabetes and cancer. Rick Doblin is a hero.

1

Client Served

Rating: 5

Psychedelic research is a fascinating and important area. The human mind is the most powerful, enigmatic concept we know - it would be an injustice not to explore and learn more about it.

4

Client Served

Rating: 5

MAPS is a great organization that does excellent work in areas spanning a variety of issues. Most recently I got to participate in a teleconference of a presentation By Andrew Weil MD at a MAPS conference in California while I was at the Cannabis Therapeutics Conference in Rhode Island. MAPs soes an outstanding job of locating and disseminating critical information for policy makers. Keep up the great work

Review from Guidestar

4

Client Served

Rating: 5

MAPS has been tremendously helpful and extremely informative. Their contact has been a real plus in my life. Their magazines are most helpful with photos of personnel and content.

Review from Guidestar

4

Client Served

Rating: 5

always updated,available and kind.able to organize and explain,devoted to the cause of making people feeling better.positive attitude and always smiling.

6

Client Served

Rating: 4

While attending a conference in San Francisco I heard a presentation from Dr. Doblin on the theraputic value of psychedelic drugs in controlled settings for patients who are troubled by traumatic memories or are fearful of dying. He made a forceful, logical case for the need to legalize research and treatment using these forbidden drugs, including cannabis. From hearing his message I am able to better make the case for legalization to my friends and neighbors.

Review from Guidestar

4

Client Served

Rating: 5

MAPS has been investigating the medical use of ibogaine, a psychedelic drug which immediately stops withdrawal symptoms from opiate addiction. I received this treatment at a clinic where MAPS has been doing studies, and was asked to participate in one of those studies. The treatment was 100% successful. I was put on suboxone, a potent opiate, by my doctor as an off-label treatment for depression. When I tried to stop taking the drug because it wasn't working, I found that I was deeply addicted to the drug and could not get off of it. I made it twelve days on 0mg with no relief from the horrible physical withdrawal. At my doctor's urging I went back on suboxone. I then learned about ibogaine treatment, and two hours after ingesting the psychedelic, all symptoms were gone! I also benefited greatly from the psychedelic experience. As my experience shows, standard pharmaceutical drugs often harm people and research into alternatives must be undertaken. MAPS is at the forefront of promoting these alternative therapies.

6

Client Served

Rating: 5

my experiences have helped me to change the world, i am not refering to this beautiful planet earth, but the world that each of us creates inside our own head.

4

Client Served

Rating: 5

I suffer from PTSD and the only thing that helped me was session with this pharmaceutical. I would like to continue with the therapy, but have been unable to due to certain laws in place.

Review from Guidestar